Trial Profile
Phase I Study of GSK233705- A Randomised, Double Blind, Placebo-controlled, 2-parts Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Inhaled Doses of GSK233705 From a Novel Dry Powder Device in Healthy Japanese Male Subjects -
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Darotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
- 01 Sep 2009 New trial record